Post-earnings recap
Reported
Mon, Nov 10, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 11.36%, likely driven by optimism surrounding their ongoing clinical trials and product development efforts. The lack of revenue figures and guidance may leave some investors cautious about the company's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | -45.71% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to advancing their pipeline despite the earnings miss. They emphasized the importance of their clinical programs.
Management did not provide specific guidance for future performance.
The company is focused on its ongoing clinical trials and product development.